Form 4: Broadwood Partners Boosts STAA Stake

Broadwood Partners, a 10% owner and director, significantly increased its beneficial ownership in STAAR Surgical Co. through multiple common stock purchases in November 2025.

Summary

• Broadwood Partners, L.P., a 10% owner and director of STAAR Surgical Co. (STAA), acquired a total of 1,599,000 shares of common stock over three days in November 2025.
• On November 19, 2025, 309,132 shares were purchased at a weighted average price of $26.4164, bringing direct beneficial ownership to 13,828,623 shares.
• On November 20, 2025, an additional 393,382 shares were acquired at a weighted average price of $27.1373, increasing direct beneficial ownership to 14,222,005 shares.
• On November 21, 2025, 797,486 shares were bought at a weighted average price of $27.8611, resulting in a direct beneficial ownership of 15,019,491 shares.
• These transactions were made pursuant to a Rule 10b5-1(c) plan.
• Neal C. Bradsher, President of Broadwood Capital, Inc. (General Partner of Broadwood Partners), also directly owns 25,900 shares.

Sentiment

Score: 8

Explanation: The substantial insider buying by a major institutional investor and director, Broadwood Partners, at increasing prices, indicates strong confidence in the company's valuation and future prospects. This is a significant positive signal for the stock.

Positives

• Significant insider buying by a 10% owner and director, Broadwood Partners, indicates strong confidence in the company's future prospects.
• The purchases were made at increasing prices ($26.4164, $27.1373, $27.8611), suggesting a belief in continued upward price momentum or undervaluation.
• The transactions were executed under a Rule 10b5-1(c) plan, which can signal a pre-planned, long-term investment strategy rather than opportunistic trading.

Future Outlook

The significant insider purchases by Broadwood Partners, a major shareholder and director, suggest a positive outlook on STAAR Surgical Co.'s future performance and valuation, although no explicit forward-looking statements were made in this filing.

Industry Context

Insider buying by a significant institutional investor and director often signals strong internal conviction about a company's strategic direction, product pipeline, or market position within the medical device industry, particularly for ophthalmic solutions like those offered by STAAR Surgical. This could be interpreted as a positive indicator for the company's competitive standing and growth potential.

Related Party Transactions

• Broadwood Capital, Inc. acts as the General Partner of Broadwood Partners, L.P., and Neal C. Bradsher is the President of Broadwood Capital, Inc. These entities and individual are considered related parties due to their control and influence over the reported transactions and beneficial ownership.

Stakeholder Impact

• Shareholders: The significant insider buying by a major investor and director could instill greater confidence in the company's future, potentially leading to increased investor interest and a positive impact on share price.
• Employees: A strong vote of confidence from a major investor might positively impact employee morale and perception of company stability and growth prospects.

Key Dates

Recommendation

The substantial and consecutive purchases of STAAR Surgical Co. common stock by Broadwood Partners, a 10% owner and director, at increasing prices, signals a very strong conviction in the company's intrinsic value and future growth trajectory. Such significant insider buying, especially from an institutional investor with board representation, is often a powerful indicator of undervaluation or anticipated positive developments not yet fully reflected in the market price. The execution under a Rule 10b5-1 plan further suggests a deliberate, long-term investment strategy. This action by a well-informed insider warrants a 'strong buy' recommendation, as it implies a high probability of future share price appreciation.

Keywords

STAAR Surgical, STAA, Broadwood Partners, Insider Buying, Form 4, Equity Acquisition, 10% Owner, Director, Stock Purchase, Rule 10b5-1